About: Severe acute respiratory syndrome coronavirus nucleocapsid protein confers ability to efficiently produce virus-like particles when substituted for the human immunodeficiency virus nucleocapsid domain

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Severe acute respiratory syndrome coronavirus nucleocapsid protein confers ability to efficiently produce virus-like particles when substituted for the human immunodeficiency virus nucleocapsid domain Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Severe acute respiratory syndrome coronavirus nucleocapsid protein confers ability to efficiently produce virus-like particles when substituted for the human immunodeficiency virus nucleocapsid domain
Creator	Wang, Chin-Tien Wang, Shui-Mei Ae, Chen Ae, Chang Arthur, Yi-Ming Yu-Fen, A
Source	Medline; PMC
abstract	We replaced the HIV-1 nucleocapsid (NC) domain with different N-coding sequences to test SARS-CoV nucleocapsid (N) self-interaction capacity, and determined the capabilities of each chimera to direct virus-like particle (VLP) assembly. Analysis results indicate that the replacement of NC with the carboxyl-terminal half of the SARS-CoV N resulted in the production of wild type (wt)-level virus-like particles (VLPs) with the density of a wt HIV-1 particle. When co-expressed with SARS-CoV N, chimeras containing the N carboxyl-terminal half sequence efficiently packaged N. However, the same was not true for the chimera bearing the N amino-terminal half sequence, despite its production of substantial amounts of VLPs. According to further analysis, HIV-1 NC replacement with N residues 2–213, 215–421, or 234–421 resulted in efficient VLP production at levels comparable to that of wt HIV-1, but replacement with residues 215–359, 302–421, 2–168, or 2–86 failed to restore VLP production to wild-type levels. The results suggest that the domain conferring the ability to direct VLP assembly and release in SARS-CoV N is largely contained between residues 168 and 421.
has issue date	2008-07-01(xsd:dateTime)
bibo:doi	10.1007/s11373-008-9265-8
bibo:pmid	18592403
has license	no-cc
sha1sum (hex)	5943d40911e2da61381868d783fa205c57cd8de3
schema:url	https://doi.org/10.1007/s11373-008-9265-8
resource representing a document's title	Severe acute respiratory syndrome coronavirus nucleocapsid protein confers ability to efficiently produce virus-like particles when substituted for the human immunodeficiency virus nucleocapsid domain
has PubMed Central identifier	PMC7088652
has PubMed identifier	18592403
schema:publication	J Biomed Sci
resource representing a document's body	covid:5943d40911e2da61381868d783fa205c57cd8de3#body_text
is schema:about of	named entity 'PRODUCE' named entity 'VIRUS-LIKE PARTICLES' named entity 'domain' named entity 'REPLACED' named entity 'NUCLEOCAPSID' named entity '168' named entity 'CODING' named entity 'CARBOXYL' named entity 'RELEASE' named entity '234' named entity '215' named entity 'SUGGEST' named entity 'SEQUENCES' named entity 'FAILED' named entity 'HALF' named entity 'EXPRESSED' named entity 'DETERMINED' named entity 'TO DIRECT' named entity 'OF EACH' named entity 'CONTAINING' named entity 'DOMAIN' named entity 'ASSEMBLY' named entity 'DIFFERENT' named entity 'BUT' named entity 'ANALYSIS' named entity 'SARS-COV' named entity 'INTERACTION' named entity 'VIRUS-LIKE PARTICLES' named entity 'ITS' named entity 'ACCORDING' named entity 'HUMAN IMMUNODEFICIENCY VIRUS' named entity 'NUCLEOCAPSID PROTEIN' named entity 'NUCLEOCAPSID' named entity 'PROTEIN ' named entity 'AMOUNTS' named entity 'BEARING' named entity 'WILDTYPE' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS' named entity 'PACKAGED' named entity 'LEVEL' named entity 'SELF' named entity 'DENSITY' named entity 'TO TEST' named entity 'EFFICIENT' named entity 'SEQUENCE' named entity 'VLPS' named entity 'CAPACITY' named entity 'VLP' named entity 'DOMAIN' named entity 'REPLACEMENT' named entity 'RESULTS' named entity 'WILD TYPE' named entity 'TERMINAL' named entity 'PARTICLE' named entity 'AMINO' named entity 'CHIMERA' named entity 'LARGELY' named entity 'PRODUCTION' named entity 'NOT TRUE' named entity 'VIRUSLIKE PARTICLE' named entity 'LEVELS' named entity 'HIV-1' covid:arg/5943d40911e2da61381868d783fa205c57cd8de3 named entity 'particles' named entity 'failed' named entity 'ability' named entity 'production' named entity 'VLP' named entity 'amino-terminal' named entity 'residues' named entity 'SARS-CoV' named entity 'domain' named entity 'determined' named entity 'nucleocapsid' named entity 'HIV-1' named entity 'carboxyl-terminal'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software